Impact of all-oral direct-acting antivirals on hepatocellular carcinoma in Vietnamese patients with chronic HCV genotype 1
The Journal of Infection in Developing Countries · 2025
DOI: 10.3855/jidc.21228 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Infection in Developing Countries, 2025. Verfasst von Thong D Vo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam. Hauptthemen laut MEDLINE: Antiviral Agents, Carcinoma, Hepatocellular, Hepacivirus, Hepatitis C, Chronic. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Introduction
Hepatitis C virus (HCV) genotype 1 is a significant cause of hepatocellular carcinoma (HCC) in Vietnam. Direct-acting antivirals (DAAs) are effective in achieving sustained virologic response (SVR), potentially reducing HCC incidence. This study evaluated how DAA regimens affect HCC incidence in Vietnamese patients with chronic liver disease related to HCV genotype 1. Methodology: A retrospective cohort study was conducted with 450 HCV-1 patients treated with DAAs at the Liver Clinic, University Medical Center Ho Chi Minh City, Vietnam. Patients were followed for a median duration of 0.5 years. Treatment regimens included combinations of NS5A inhibitors with NS3/4A protease inhibitors or NS5B polymerase inhibitors. Data on demographics, baseline clinical characteristics (e.g., alpha-fetoprotein, albumin levels), and liver function were collected before initiating DAA treatment. Follow-up data, including SVR rates and HCC incidence, were assessed at the end of treatment and during the post-treatment observation period (median follow-up of 0.5 years). This approach allowed us to compare pre-treatment baseline data with post-treatment outcomes to evaluate the impact of DAA therapy on HCC risk factors and incidence.
Results
SVR was achieved in 94.8% of patients, with an HCC incidence of 1.1% at 1 year for SVR patients, versus 6.5% for non-SVR patients. Significant risk factors for HCC included hypoalbuminemia, elevated alpha-fetoprotein levels, and non-SVR status.
Conclusions
DAAs significantly reduce HCC incidence in Vietnamese patients with HCV-1; however, ongoing surveillance is essential for high-risk patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, School of Medicine, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
- Faculty of Pharmacy, University of Medicine and Pharmacy at Ho Chi Minh City, Ho Chi Minh City, Vietnam.
Zitieren
APA
Vo, T. D., & Bui, V. T. (2025). Impact of all-oral direct-acting antivirals on hepatocellular carcinoma in Vietnamese patients with chronic HCV genotype 1. The Journal of Infection in Developing Countries. https://doi.org/10.3855/jidc.21228
Vancouver
Vo TD, Bui VT. Impact of all-oral direct-acting antivirals on hepatocellular carcinoma in Vietnamese patients with chronic HCV genotype 1. The Journal of Infection in Developing Countries. 2025. doi:10.3855/jidc.21228
BibTeX
@article{Vo2025,
author = {Vo, Thong D and Bui, Van Tt},
title = {Impact of all-oral direct-acting antivirals on hepatocellular carcinoma in Vietnamese patients with chronic HCV genotype 1},
journal = {The Journal of Infection in Developing Countries},
year = {2025},
doi = {10.3855/jidc.21228}
}
EUVIMED